e-ISSN: 0975-1556, p-ISSN:2820-2643

Available online on www.ijpcr.com

International Journal of Pharmaceutical and Clinical Research 2023; 15(6); 2327-2333

Original Research Article

Study on the Efficacy of Budesonide and Formoterol with That of Inhaled Corticosteroid in Mild Asthma

Saidas B. Linganwad[1], Shah Ketan Jaysukhlal[2]

[1]Assistant Professor, Dept. of Medicine, Vedantaa Institute of Medical Sciences, Saswand, Dhundalwadi, Dahanu, Palghar, Maharashtra, 401606

[2]Assistant Professor, Dept. of Medicine, Vedantaa Institute of Medical Sciences, Saswand, Dhundalwadi, Dahanu, Palghar, Maharashtra, 401606

Received: 16-03-2023 / Revised: 18-04-2023 / Accepted: 27-05-2023

Corresponding author:Dr. Shah Ketan Jaysukhlal

Conflict of interest: Nil

Abstract:

Introduction: Asthma Exacerbations may still occur in people including well accepted asthma symptoms, necessitating the use of preventative treatments. One widely accepted indicator of the likelihood of exacerbations is poor symptom management. A control-based approach is recommended by the Global Initiative for Asthma (GINA) assessment for asthma planning, with therapeutically as well as non-pharmacological therapeutic interventions based on evaluations of possible causes including symptom control, adjustments are made continuously. Exacerbations may still occur in people including well accepted asthma symptoms, necessitating the use of preventative treatments. One widely accepted indicator of the likelihood of exacerbations is poor symptom management.

Aims and Objectives: To investigate the efficacy between formoterol and budesonide with that of Inhaled Corticosteroid in mild form of asthma.

Methods: This study was conducted during the period of one year on 60 patients who were grouped into two groups. One group was treated with inhaled corticosteroids (ICS) and the other group with a combination of ICS and formoterol with 30 patients in each group. Group A patients received 100 µg inhaled budesonide and group B received combination of 100 µg inhaled budesonide and 4.5 µg formoterol. The study was carried during the period one Year. Baseline characteristics were determined before the intervention and the outcome assessments were statistically analyzed after the intervention.

Results: The FEV1 value is 4.07 in group A and 5.92 in group B. the days with symptoms are high in group A (23.8) compared to group B (21.9). The PEF value is high in group B (32.09) compared to group A (15.23). The study has shown that there is improvement in exacerbation in patients with both ICS and formoterol as compared to the patients with ICS alone ($p<0.05$). Similar significant findings have been observed in sleepless nights among the patients who received ICS and formoterol.

Conclusion: The study concluded that addition of formoterol with existing ICS therapy will may improve the asthma related factors and hence quality of life than to increase the dosage of ICS.

Keywords: Formoterol, Corticosteroid, Asthma, Exacerbation.

Introduction

About 70% of people with asthma in the community have mild cases, which place a heavy financial burden on society [1]. Despite this, those (patients) with a more serious situation of asthma have been the main focus of the majority of studies. Achieving good symptom management and lowering patient probability of future events, such as exacerbations, are protracted goals of asthma treatment [3]. Exacerbations may still occur in people including well accepted asthma symptoms, necessitating the use of preventative treatments. One widely accepted indicator of the likelihood of exacerbations is poor symptom management [4].

Regarding the risk of exacerbations, mild asthma places a significant load [5]. Inhaled glucocorticoid therapy lowers the risk [6], but it is frequently not used as advised due to patients' resistance to taking it when their symptoms are minor and infrequent [7] and the resistance of medical practitioners to prescribe it as a maintenance medication. Use of an as-needed reliever therapy inhaler that combines an inhaled glucocorticoid in addition to a fast-onset β2-agonist is an alternative strategy utilizes of patients' propensity for using relief treatment when they experience symptoms [8–10] as well as gives them the ability to manage how much inhaled glucocorticoid therapy they use in accordance with their unique needs for treating their asthma.

A control-based approach is recommended by the Global Initiative for Asthma (GINA) assessment for asthma planning, with therapeutically as well as non-pharmacological therapeutic interventions based on evaluations of possible causes including symptom control, adjustments are made continuously. A move increase in treatment is indicated if asthma symptoms are still not adequately managed or if exacerbations continue despite strong compliance with right training with the patient's current inhaled medication [3]. Low-dose inhaled corticosteroids (ICS) are advised for Step 2 treatment, along with short-actingβ 2-agonists (SABA) for pain relief when necessary [3]. The primary drug rehabilitation aimed at severe as well as slight asthma in adolescents in addition to adults is inhaled corticosteroid (ICS)-long acting β2-agonist (LABA) treatment [11, 12].

For patients at treatment phases 3, 4, and 5, the Global Initiative for Asthma (GINA) proposes two ICS-LABA treatment regimens: a single inhaler setup Short-acting β2-agonist (SABA) as a reliever and ICS-formoterol as a maintenance therapy (SMART) or ICS-LABA as a maintenance therapy (ICS-LABA maintenance desirable SABA). When the ICS-LABA maintenance combination does not contain formoterol as the LABA component, as-needed ICS-formoterol is the recommended reliever at all GINA phases [13].

In individuals who are using GINA Phase 2, 3, or 4 drugs but still have poor asthma controlling, researchers have formerly reported BUD/FORM MRT is superior to elevated dose ICS in terms of enhancing symptom management to reduce exacerbations, as shown by a post-hoc assessment of 5 studies [9]. The majority of the participants in these research, however, had neglected indication regulated at admission, using relievers on average 1.7 to 2.4 times per day, well beyond the standard of SABA use of ≥3 times per week at which a step-up would typically be deliberated [14].The effectiveness of BUD/FORM MRT in individuals having lower, better regulated illness at trial entrance, i.e. those who use pain relievers less frequently when using a small dose ICS (≤400μg/day BUD corresponding), is thus a pertinent concern. Their post-hoc research evaluated the efficacy of BUD/FORM MRT in these

individuals, subdivided with initial relieving usage, in contrast to the standard strategy of a larger, fixed-dose combination of BUD + SABA as required [14], in in terms of increasing exacerbation frequency, lung function, overall relieving were using.

Materials and methods

Study design

A study was conducted on 60 patients who were grouped into two groups one group was treated with inhaled corticosteroids (ICS) and the other group with a combination of ICS and formoterol with 30 members in each group. Group A patients received 100 µg inhaled budesonide and group B received combination of 100 µg inhaled budesonide and 4.5 µg formoterol. Time until the first severe asthma exacerbation, which was determined by the investigator to require oral corticosteroid treatment, hospitalization, or emergency medical care for worsening asthma, or (2) a reduction in morning PEF of 25% from baseline over two consecutive days, were the primary outcomes. Modifications in morning PEF anticipated FEV1%, the proportion of days with symptoms, the proportion of asthma awakenings, the number of rescue inhalations, and the rate of severe asthma exacerbations per patient per year were the secondary outcomes.

Inclusion and exclusion criteria

patients who came to the outpatient department of our hospital, who provided informed consent, and who followup the study are included in the study. Of total 60 patients are included in the study. Patients who do not follow up on the study, who do not provide informed consent are not included in the study. Patients with severe exacerbations in the initial months are excluded from the study.

Statistical analysis

Time until the first severe asthma exacerbation, which was determined by the investigator to require oral corticosteroid treatment, hospitalization, or emergency medical care for worsening asthma, or (2) a reduction in morning PEF of 25% from baseline over for two consecutive days, were the primary outcomes. Modifications in morning PEF anticipated FEV1%, the proportion of days with symptoms, the proportion of asthma awakenings, the number of rescue inhalations, and the rate of severe asthma exacerbations per patient per year were the secondary outcomes.

Ethical approval

The patients were given thorough information about the study by the authors. The patient's permission has been obtained. The hospital's Ethical Committee has approved the study process.

Results

The patients were divided into two groups group A and Group B each with 30 patients and receiving inhaled corticosteroids and inhaled corticosteroids plus formoterol respectively. The mean of patients is 30.7 and 31.4 in group A and group B respectively. Females were 60% in group A and 65.7% in group B. the other characteristics were significant in both groups (table 1).

Table 1: Demographic characteristics of patients in this study

Variable	Group A Inhaled corticosteroids (ICS) (n=30)	Group B ICS+formoterol(n=30)
Age	30.7	31.4
Female sex, %	21 (60)	23 (65.7)
PEF morning, L/min	2 (5.7)	3 (8.5)
Prebronchodilator FEV1,	90.4 (0.95)	89.7 (0.98)

% pred		
Rescue inhalations, n	0.97 (0.2)	0.85 (0.07)
Days with symptoms, %	42.1 (2.6)	38.2 (2.5)
Nights with awakening, %	12.4 (1.5)	12.3 (1.6)

The FEV1 value is 4.07 in group A and 5.92 in group B. the days with symptoms are high in group A (23.8) compared to group B (21.9). The PEF value is high in group B (32.09) compared to group A (15.23). Group A has higher night awakenings compared to group B (table 2). The study has shown that there is improvement in exacerbation in patients with both ICS and formoterol as compared to the patients with ICS alone ($p<0.05$). Similar significant findings have been observed in sleepless nights among the patients who received ICS and formoterol.

Table 2: Outcome assessment of both the groups in this study

Variable	**Group A Inhaled corticosteroids (ICS) (n=30)**	**Group B ICS+ Formoterol (n=30)**	***p*-value**
Change in FEV1, %pred	4.07	5.92	0.065
Change in PEF morning, L/min	15.23	32.09	0.031
Number of rescue inhalations per day	0.53	0.53	0.06
Days with symptoms, %	23.8	21.9	0.031
Rate per year of severe exacerbations	0.4	0.31	0.014
Nights with awakening, %	3.4	2.8	0.024

Discussion

Jenkins et al. (2017) conducted a study and published the results of a post-hoc analysis. There were 1239 patients covered in all. In comparison to fixed-dose budesonide, budesonide/formoterol MRT significantly reduced the rate of severe exacerbations in patients using 1-2 (42%) and >2 (39%) relief occasions per day, but not those using <1 reliever occasion per day (35%). All therapies drastically enhanced mean FEV1 from base, although budesonide/formoterol MRT saw increases that were much larger in all relieving using groups. The reduced reliever usage base was significantly greater using /formoterol MRT than fixed-dose budesonide in individuals using 1-2 and >2 reliever occasions/day. The therapies advantage of budesonide/formoterol MRT over elevated, fixed-dose budesonide and also short-acting β2-agonist was seen in Step-2 patients who is using comparatively slight painkillers, confirming the notion that budesonide/formoterol MRT may be useful once asthma is unregulated with low-dose inhaled corticosteroid [14].

Beasley et al. (2022) conducted research and published a meta-analysis and systematic review. A total of 4863 patients were enrolled, with 3034 (62.4%) women and an average age of 39.8 (16.3) years. While attempting to transfer sick people with unregulated asthma at GINA step 3 (n=1950) to SMART at the other step 3 or 4 was connected with a considerable duration towards first acute asthmatic exacerbation, ramping up to achieve four main objectives inhaled corticosteroid-long-acting β2-agonist preservation plus short-actingβ2-agonist reliever was connected with a 29% enhanced danger chronic asthma exacerbations (HR: 0.71). Among patients who had untreated asthma

at stages 3 through 4, shifting to SMART was linked to a greater time between the first chronic asthma exacerbation as well as a 30% decreased incidence comparing to remaining with the current treatment process (n=2913) (HR: 0.70). In this comprehensive study as well as meta-analysis, it was discovered that SMART was linked to a prolonged duration to the first chronic asthma exacerbation in individuals with inadequately chronic asthma once contrasted to a step up or resume of GINA step with maintenance inhaled corticosteroid-long acting β2-agonist as well as short-acting β2-agonist reliever. These findings imply that if a person or adolescent receiving therapeutic interventions at GINA steps 3 or 4 has inadequately regulated asthma, having switched to the SMART routine is preferable to moving up or trying to continue the GINA step with therapy maintenance inhaled corticosteroid-long-acting β2-agonist plus short-acting β2-agonist reliever treatment [15].

SYGMA studies were investigated and published by Fitzgerald et al. in 2021. 3366 patients in the budesonide-formoterol as-needed group and 3369 patients in the budesonide maintenance group were included in the pooled analysis, with AEs occurring in 40.8% and 42.5% of patients, respectively. Upper respiratory tract infections caused by viruses and URTI were frequent adverse events. Asthma-related termination rates were equivalent for SAE, DAE, and between maintenance budesonide and as-needed budesonide-formoterol. For each regimen containing budesonide, impendingresidentin addition to systemic corticosteroid class side effects were documented in less than ≤ 1% of patients. In SYGMA 1, As-needed terbutaline (n=1277) groups had higher rates of AEs (42.7 vs. 38.0%), DAEs (2.9 vs. 0.8%), and asthma-related discontinuations (1.6 vs. 0.3%), compared to As-needed budesonide-formoterol (n=1277) groups. Patients with mild asthma typically tolerate budesonide-formoterol anti-inflammatory reliever medication well, and it has a comparable safety profile as budesonide taken daily. There were no newly discovered safety signals [16].

Budesonide-formoterol as needed for mild asthma was examined and published in a controlled trial by Beasley et al. (2019). Of the 675 patients that underwent randomization, 668 were included in the analysis. The annualised exacerbation rate was not statistically different from the rate in the budesonide maintenance group (P=0.65) and was lower in the budesonide-formoterol group than in the albuterol group (P0.001). In comparison to both the albuterol group (9 vs. 23; relative risk) and the budesonide maintenance group, the number of severe exacerbations was reduced in the budesonide-formoterol group (9vs.21 relative risk). In the budesonide-formoterol group, the mean (±SD) daily dose of budesonide was 107±109μg, while in the budesonide maintenance group, it was 222±113μg. The frequency and kind of adverse events recorded were in line with both reports from clinical use and those from earlier trials. Budesonide-formoterol administered as needed outperformed albuterol used as needed in an open-label trial including adults with mild asthma for preventing asthma attacks [17].

Conclusion

The study concluded that addition of formoterol with existing ICS therapy will may improve the asthma related factors and hence quality of life than to increase the dosage of ICS. Adding inhaled formoterol to patients who were already on a low dose of inhaled corticosteroids more successfully decreased asthma exacerbations and enhanced asthma control than increasing the dose of inhaled corticosteroids. According to the current study, formoterol can be added to lower

dosages of inhaled corticosteroids than are generally advised in order to improve asthma management. The study has brought forward an important therapeutic point in proper and effective management of asthma.

Reference

1. O'Byrne PM, Parameswaran K. Pharmacological management of mild or moderate persistent asthma. Lancet. 2006; 368:794–803.
2. Sadatsafavi M, Lynd L, Marra C, Carleton B, Tan WC, Sullivan S, Fitzgerald JM. Direct health care costs associated with asthma in British Columbia. Can Respir J. 2010; 17:74–80.
3. GINA Global strategy for asthma management and prevention. Updated 2015.
4. Bateman ED, Reddel HK, Eriksson G, Peterson S, Ostlund O, Sears MR, Jenkins C, Humbert M, Buhl R, Harrison TW, Quirce S, O'Byrne PM. Overall asthma control: the relationship between current control and future risk. J Allergy Clin Immunol. 2010; 125:600–8. e6.
5. Dusser D, Montani D, Chanez P, et al. Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations. Allergy 2007;62: 591-604.
6. Reddel HK, Busse WW, Pedersen S, et al. should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. Lancet. 2017;389: 157-66.
7. Cochrane MG, Bala MV, Downs KE, Mauskopf J, Ben-Joseph RH. Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique. Chest. 2000; 117:542-50.
8. Beasley R, Weatherall M, Shirtcliffe P, Hancox R, Reddel HK. Combination corticosteroid/β-agonist inhaler as reliever therapy: a solution for intermittent and mild asthma? J Allergy Clin Immunol. 2014; 133:39-41.
9. O'Byrne PM, Jenkins C, Bateman ED. The paradoxes of asthma management: time for a new approach? EurRespir J 2017;50(3):1701103.
10. Beasley R, Bird G, Harper J, Weatherall M. The further paradoxes of asthma management: time for a new approach across the spectrum of asthma severity. Eur Respir J 2018; 52(5):1800694.
11. British Thoracic Society/SIGN. BTS/SIGN British guideline on the management of asthma. Published 2019. Accessed January 15, 2023.
12. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Published 2018. Accessed January 15, 2023.
13. Global Initiative for Asthma (GINA). 2021 GINA report, global strategy for asthma management and prevention. Published 2021. Accessed January 15, 2023.
14. Jenkins CR, Eriksson G, Bateman ED, Reddel HK, Sears MR, Lindberg M, O'Byrne PM. Efficacy of budesonide/formoterol maintenance and reliever therapy compared with higher-dose budesonide as step-up from low-dose inhaled corticosteroid treatment. BMC pulmonary medicine. 2017 Dec;17(1):1-8.
15. Beasley R, Harrison T, Peterson S, Gustafson P, Hamblin A, Bengtsson T, Fagerås M. Evaluation of Budesonide-Formoterol for Maintenance and Reliever Therapy Among Patients with Poorly Controlled Asthma: A Systematic Review and Meta-analysis. JAMA network open. 2022 Mar 1;5(3): e220615.
16. FitzGerald JM, O'Byrne PM, Bateman ED, Barnes PJ, Zheng J, Ivanov S, Lamarca R, Larsdotter U, Emerath U, Jansen G, Puu M. Safety of as-needed budesonide-formoterol in mild asthma:

data from the two phase III SYGMA studies. Drug safety. 2021 Apr; 44(4): 467-78.
17. Beasley R, Holliday M, Reddel HK, Braithwaite I, Ebmeier S, Hancox RJ, Harrison T, Houghton C, Oldfield K, Papi A, Pavord ID. Controlled trial of budesonide–formoterol as needed for mild asthma. New England Journal of Medicine. 2019 May 23;380(21):2020-30.